Today: 16 April 2026
Qualcomm stock slips after Daiwa downgrade as traders eye Samsung launch, memory squeeze
12 February 2026
2 mins read

Qualcomm stock slips after Daiwa downgrade as traders eye Samsung launch, memory squeeze

New York, February 12, 2026, 16:08 EST — After-hours trading underway

  • Qualcomm dropped 1.8% through the session, then barely moved after hours.
  • Daiwa cut its rating to neutral, giving the stock a $140 price target.
  • Investors are watching handset memory constraints ahead of Samsung’s Feb. 25 flagship event.

Qualcomm fell 1.8% on Thursday, wrapping up the day just above $138.5. Shares were active again after the 4 p.m. ET bell. Chip names lost ground as well, with the Nasdaq off about 2%.

Daiwa Securities downgraded Qualcomm, shifting the stock to neutral from outperform and setting a $140 price target, according to an MT Newswires note. Qualcomm has picked up a handful of analyst rating changes since its last quarterly report.

This one’s got some heft—the stock story has snapped back to smartphones, at least for this quarter. On last week’s fiscal Q1 call, CFO Akash Palkhiwala pointed to “increasing demand for memory solutions in AI data centers is driving near-term uncertainty in memory supply and pricing for handset OEMs,” as he described the latest headwinds for device makers. https://s204.q4cdn.com/645488518/files/doc…

Chief executive Cristiano Amon was blunt in the Q&A: “100% related to memory,” he said, pointing straight at DRAM supply in phones. Qualcomm is guiding for fiscal second-quarter revenue between $10.2 billion and $11 billion, and it sees adjusted earnings per share landing somewhere from $2.45 to $2.65.

The stock hasn’t shaken off its troubles. After earnings, Amon told Reuters that memory shortages are pinching smartphone demand and led to the miss. Bob O’Donnell, chief analyst at TECHnalysis Research, said the memory squeeze could last “the next several quarters” and singled out China as a pressure point. https://www.reuters.com/world/china/qualco…

Handset troubles aren’t getting much airtime from investors right now; their focus has shifted to Qualcomm’s bets outside phones and whether those can pull their weight this quarter. The company’s pushed hard into automotive and connected devices, and data-center chips have drawn plenty of buzz lately. Yet, the share price keeps swinging in response to every fresh phone supply-chain headline.

Samsung’s Galaxy Unpacked event kicks off Feb. 25 in San Francisco, putting the next launch window in sharp focus. Qualcomm, supplier of Snapdragon chips powering many top Android phones, usually adjusts both orders and product mix as each fresh model rolls out.

“Memory” might stick around longer than bulls would like. If handset makers keep slashing their build schedules—trying to juggle component shortages and pricing—Qualcomm’s chip shipments could feel the squeeze, regardless of how end-demand holds up.

There’s also share to consider. Qualcomm’s fight with MediaTek for Android dominance hasn’t let up. Meanwhile, Apple and Samsung keep advancing their in-house chips—potentially shrinking Qualcomm’s slice of the next cycle.

Friday brings the question: will the downgrade set off more target slashes, or do chip stocks claw back any losses after the recent rout? Looking ahead, earnings land May 6.

Stock Market Today

  • ASX Penny Stocks to Watch April 2026: Frontier Energy and Imricor Medical Systems
    April 15, 2026, 10:34 PM EDT. As the ASX approaches 9,000 points, penny stocks offer potential growth amid mixed market signals. Frontier Energy Limited (ASX:FHE), valued at A$146.27 million, targets renewable energy with a promising Waroona Project expected to yield A$32 million annually from 2027. The company is debt-free and recently appointed Jamie Cullen as Executive Chairman. Imricor Medical Systems (ASX:IMR), a medical device firm with a A$632.27 million market cap, posted US$0.29 million revenue in 2025. Despite a -219.72% return on equity, it holds more cash than debt and expects 89% revenue growth and a 32% stock price rise. Both stocks remain pre-revenue but show strong leadership and financial stability amid local and global market challenges.

Latest article

Norse Atlantic Cancels All LAX Summer Flights as Fuel Costs Force Los Angeles Retreat

Norse Atlantic Cancels All LAX Summer Flights as Fuel Costs Force Los Angeles Retreat

16 April 2026
Norse Atlantic Airways has canceled all planned summer flights from Los Angeles to London Gatwick, Paris, and Rome, citing surging jet fuel costs. The airline launched a $110 million rights issue, secured a $70 million bridge loan, and withdrew its 2026 outlook. Routes disappeared from booking systems on April 14. Norse had been the only scheduled operator on the Gatwick-Los Angeles route.
S&P 500 Hits Record High as Iran Deal Hopes, Bank Earnings Lift Wall Street

S&P 500 Hits Record High as Iran Deal Hopes, Bank Earnings Lift Wall Street

16 April 2026
The S&P 500 closed at a record 7,022.95 and the Nasdaq at 24,016.02 on Wednesday, erasing losses from the March selloff tied to the Feb. 28 conflict. Bank of America reported $8.6 billion in first-quarter net income, up 17%, while Morgan Stanley posted record revenue. Talks between Washington and Tehran raised hopes for easing oil supply fears, but Brent crude stayed elevated at $94.93 a barrel.
Tesla’s U.S. Solar Bet Faces China Export Threat as Energy Arm Becomes More Profitable Than Cars

Tesla’s U.S. Solar Bet Faces China Export Threat as Energy Arm Becomes More Profitable Than Cars

16 April 2026
China is considering export restrictions on advanced solar-manufacturing equipment to the U.S., potentially affecting Tesla’s plans for new factories, sources told Reuters. Tesla aims to buy $2.9 billion in solar-panel equipment from China and expand U.S. solar production. China produces over 80% of global solar panel components. No final decision has been made, and consultations remain preliminary.
Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

15 April 2026
Hims & Hers Health shares rose 14% to $24.29 after the FDA said it will review restrictions on several peptides, including BPC-157 and TB-500. The agency set a July advisory meeting and will remove some peptides from its safety-risk list within a week. Hims, which acquired a California peptide facility last year, reported $2.35 billion in 2025 revenue and 2.511 million subscribers.
Silver price slides 9% and SLV sinks as traders brace for Friday’s US CPI
Previous Story

Silver price slides 9% and SLV sinks as traders brace for Friday’s US CPI

Standard Chartered taps B2C2 to speed “fiat-to-crypto” transfers for big investors
Next Story

Standard Chartered taps B2C2 to speed “fiat-to-crypto” transfers for big investors

Go toTop